Note 11 - Related Party Transactions |
9 Months Ended | |||
|---|---|---|---|---|
Sep. 30, 2020 | ||||
| Notes to Financial Statements | ||||
| Related Party Transactions Disclosure [Text Block] |
The Company uses Moores Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services to the Company. Dr. Stephen Howell is a member of our Scientific Advisory Board and former Acting Chief Medical Officer of Aptose up to January 1, 2020, and is also a Professor of Medicine at UCSD and oversees the laboratory work. The work is completed under the terms of research services agreements executed in March 2015 and has been extended annually. These transactions are in the normal course of business and are measured at the amount of consideration established and agreed to by the related parties.During the comparative period ended
September 30, 2019, while Dr. Howell was Acting Chief Medical Officer, the Company recorded $154 thousand in research and development expenses related to the agreement. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|